Archive · 21 Jul 2025
India's Indigenous Malaria Vaccine Shows Promising Results
Scientists in India have created a new vaccine called AdFalciVax to fight malaria.
This vaccine is special because it's made in India and works in a new way, targeting two stages of the malaria-causing parasite.
The goal is to protect people from getting malaria and also stop the disease from spreading in communities.
The vaccine is designed to be affordable and is currently being tested.
The first human trials are expected to start in about two years.
India's first indigenous malaria vaccine, AdFalciVax, has shown good efficacy in preclinical stages.
The vaccine targets two critical stages of the Plasmodium falciparum parasite.
It aims to protect against human infection and reduce community transmission.
AdFalciVax is a cost-effective formulation using pharmaceutically acceptable carriers.
Phase 1 clinical trials are expected to take approximately two years.
- Who
- The Indian Council of Medical Research (ICMR) is developing the vaccine.
- What
- Development of an indigenous malaria vaccine, AdFalciVax, with positive preclinical results.
- When
- The vaccine is currently in the early R&D phase with Phase 1 trials expected to begin in approximately two years.
- Where
- India.
- Why
- To contribute significantly toward malaria eradication by preventing infection and minimizing community transmission.
- Vaccine Name
- AdFalciVax
- Developed by
- Indian Council of Medical Research (ICMR)
- Target
- Plasmodium falciparum parasite
- Goal
- Prevent infection and reduce community transmission of malaria
- Stage
- Preclinical
- Expected Trial Time
- Approximately two years